Table 2.
Clinical and Angiography Characteristics
| Variables | MACE, n=50 | No MACE, n=182 | P value |
|---|---|---|---|
| Age, y | 55.7±10.6 | 51.0±10.2 | 0.004 |
| Men | 38 (76.0) | 149 (81.9) | 0.353 |
| Current smoking | 32 (64.0) | 136 (74.7) | 0.133 |
| Dyslipidemia | 20 (40.0) | 92 (50.5) | 0.186 |
| Hypertension | 15 (30.0) | 45 (24.7) | 0.451 |
| Diabetes | 9 (18.0) | 16 (8.8) | 0.063 |
| CKD | 2 (4.0) | 3 (1.6) | 0.310 |
| Clinical presentation | |||
| STEMI | 40 (80.0) | 157 (86.3) | 0.273 |
| NSTE‐ACS | 10 (20.0) | 25 (13.7) | |
| Total ischemic time, min | 419.9±289.0 | 335.7±238.7 | 0.059 |
| Laboratory data | |||
| TG, mg/dL | 144.5±76.0 | 142.5±100.8 | 0.898 |
| TC, mg/dL | 173.5±40.5 | 173.2±39.4 | 0.956 |
| LDL‐C, mg/dL | 105.4±31.8 | 105.8±32.7 | 0.930 |
| HDL‐C, mg/dL | 50.8±16.1 | 50.6±13.6 | 0.945 |
| Hs‐CRP, mg/L | 5.5±5.0 | 6.5±5.0 | 0.823 |
| HbA1c, % | 5.9±1.1 | 6.0±1.1 | 0.331 |
| CK‐MB, μg/L | 123.0 (58.3–200.1) | 149.1 (35.5–285.8) | 0.240 |
| cTnI, μg/L | 42.0 (11.6–79.8) | 45.2 (8.6–123.1) | 0.379 |
| NT‐proBNP, pg/mL | 396.0 (145.8–1548.5) | 617.5 (166.5–1216.8) | 0.845 |
| Medications | |||
| Aspirin | 50 (100) | 182 (100) | … |
| Clopidogrel | 14 (28.0) | 62 (34.1) | 0.418 |
| Ticagrelor | 36 (72.0) | 120 (65.9) | 0.418 |
| Statins | 50 (100) | 182 (100) | … |
| ACEI/ARB | 31 (62.0) | 108 (59.3) | 0.734 |
| β‐Blocker | 38 (76.0) | 128 (70.3) | 0.431 |
| Lesion location | |||
| LAD | 37 (74.0) | 130 (71.4) | 0.945 |
| LCX | 4 (8.0) | 14 (7.7) | |
| RCA | 9 (18.0) | 38 (20.9) | |
| RVD, mm | 3.1±0.6 | 3.1±0.6 | 0.467 |
| MLD, mm | 1.3±0.4 | 1.4±0.5 | 0.163 |
| DS, % | 56.2±10.6 | 54.5±10.5 | 0.323 |
| Lesion length, mm | 15.9±5.1 | 16.9±5.9 | 0.249 |
| Manual thrombectomy | 40 (80.0) | 127 (69.8) | 0.154 |
| GPI | 24 (48.0) | 99 (54.7) | 0.401 |
| Initial TIMI flow grade | |||
| 0–1 | 37 (74.0) | 138 (75.8) | 0.724 |
| 2–3 | 13 (26.0) | 44 (24.2) | |
Values are mean±SD, n (%), or median (25th–75th percentiles).
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; CK‐MB, creatine kinase myocardial band; cTnI, cardiac troponin I; DS, diameter stenosis; GPI, glycoprotein IIb/IIIa inhibitor; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; Hs‐CRP, high‐sensitivity C‐reactive protein; LAD, left anterior descending artery; LCX, left circumflex artery; LDL‐C, low‐density lipoprotein cholesterol; MACE, major adverse cardiovascular events; MLD, minimal lumen diameter; NSTE‐ACS, non–ST‐segment–elevation acute coronary syndrome; NT‐pro BNP, N‐terminal pro‐B type natriuretic peptide; RCA, right coronary artery; RVD, reference vessel diameter; STEMI, ST‐segment–elevation myocardial infarction; TC, total cholesterol; TG, triglyceride; and TIMI, thrombolysis in myocardial infarction.